Interestingly, the treatment with anti-RANKL in mice affected by chronic social defeat stress and depression-like syndrome ameliorates the phenotypes, suggesting a putative novel therapeutic use of anti-RANKL antibodies in human depression (Zhang et al., 2020). Here, TNFSF11 is linked to depressive disorder.